Diagnosis and treatment of primary central nervous system lymphoma: A report of nine cases and literature review

Wang,Jun; Guo,Zongze; Ma,Ermeng; Xing,Deguang; Qiu,Bo; Wang,Yunjie

doi:10.3892/ol.2015.2903

Diagnosis and treatment of primary central nervous system lymphoma: A report of nine cases and literature review

Authors:
- Jun Wang
- Zongze Guo
- Ermeng Ma
- Deguang Xing
- Bo Qiu
- Yunjie Wang
View Affiliations

Affiliations: Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: January 27, 2015 https://doi.org/10.3892/ol.2015.2903
Pages: 1795-1801

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare, highly malignant tumor type of the nervous system and is associated with poor prognosis. To investigate the efficacy of current treatment strategies for PCNSL, the present study retrospectively analyzed the clinical and pathological features, imaging results, clinical management, and prognoses of nine patients with PCNSL. Postoperative pathological examination confirmed a diagnosis of lymphoma in all the patients and the adopted treatment regimens were as follows: Stereotactic biopsy in combination with methylprednisolone (MP) and methotrexate (MTX) and/or radiotherapy; craniotomy in combination with dexamethasone or MP and/or radiotherapy; and neuroendoscopic surgery in combination with MP and MTX. The follow‑up period was 5‑27 months with an average duration of 10.1 months. After the initial three months of follow‑up, the clinical symptoms of all the patients were significantly improved, with the tumor disappearing in seven patients and evidently reducing in size in two patients. However, six patients exhibited tumor recurrence, three of whom eventually succumbed to the disease during the follow‑up period. Currently, comprehensive treatment strategies based on a combination of stereotactic biopsy, chemotherapy and radiotherapy are recommended for the treatment of PCNSL. However, the effectiveness of these treatments remains unsatisfactory. Thus, future studies are required to investigate methods for improving the efficacy of PCNSL treatment strategies.

View Figures

View References

1	Rubenstein J, Ferreri AJ and Pittaluga S: Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 49(Suppl 1): 43–51. 2008. View Article : Google Scholar : PubMed/NCBI
2	Yoon JH, Kang HJ, Kim H, et al: Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience. J Korean Med Sci. 27:1378–1384. 2012. View Article : Google Scholar : PubMed/NCBI
3	Bhagavathi S and Wilson JD: Primary central nervous system lymphoma. Arch Pathol Lab Med. 132:1830–1834. 2008.PubMed/NCBI
4	Phillips EH, Fox CP and Cwynarski K: Primary CNS lymphoma. Curr Hematol Malig Rep. 9:243–253. 2014. View Article : Google Scholar : PubMed/NCBI
5	Haque S, Law M, Abrey LE and Young RJ: Imaging of lymphoma of the central nervous system, spine, and orbit. Radiol Clin North Am. 46:339–361. 2008. View Article : Google Scholar : PubMed/NCBI
6	Nayak L and Batchelor TT: Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol. 14:539–552. 2013. View Article : Google Scholar : PubMed/NCBI
7	Perini GF, Campregher PV, Santos FP and Hamerschlak N: Primary central nervous system lymphoma: what a neurologist/neurosurgeon should know? Arq Neuropsiquiatr. 71:254–257. 2013. View Article : Google Scholar : PubMed/NCBI
8	Brastianos PK and Batchelor TT: Primary central nervous system lymphoma: overview of current treatment strategies. Hematol Oncol Clin North Am. 26:897–916. 2012. View Article : Google Scholar : PubMed/NCBI
9	Gallop-Evans E: Primary central nervous system lymphoma. Clin Oncol (R Coll Radiol). 24:329–338. 2012. View Article : Google Scholar
10	Olson JE, Janney CA, Rao RD, et al: The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 95:1504–1510. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kürtüncü M, Tüzün E, Durmuş H, Mutlu M, Akman-Demir G and Eraksoy M: Primary cerebral lymphoma with a 5-year remission to single-agent corticosteroids. Leuk Lymphoma. 50:1552–1553. 2009. View Article : Google Scholar : PubMed/NCBI
12	Jezersek Novakovic B: Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 - a single centre report. Radiol Oncol. 46:346–353. 2012. View Article : Google Scholar
13	Bellinzona M, Roser F, Ostertag H, Gaab RM and Saini M: Surgical and removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 31:100–105. 2005. View Article : Google Scholar : PubMed/NCBI
14	Weller M, Martus P, Roth P, Thiel E and Korfel A; German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol. 14:1481–1484. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ferreri AJ, Abrey LE, Blay JY, et al: Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol. 21:2407–2414. 2003. View Article : Google Scholar : PubMed/NCBI
16	Schorb E, Kasenda B, Atta J, et al: Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica. 98:765–770. 2013. View Article : Google Scholar : PubMed/NCBI
17	Pennese E, Vergine C, Matera R, Dargenio M, Forese P and Di Renzo N: Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support. Leuk Lymphoma. 52:2188–2189. 2011. View Article : Google Scholar : PubMed/NCBI
18	Thiel E, Korfel A, Martus P, et al: High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 11:1036–1047. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ferreri AJ, Verona C, Politi LS, Chiara A, Perna L, Villa E and Reni M: Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys. 80:169–175. 2011. View Article : Google Scholar
20	Correa DD, Shi W, Abrey LE, et al: Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol. 14:101–108. 2012. View Article : Google Scholar :
21	Illerhaus G: Primary CNS lymphoma. Dtsch Med Wochenschr. 138:2515–2518. 2013.(In German). PubMed/NCBI
22	Omuro A, Taillandier L, Chinot O, et al; ANOCEF Group (French Neuro-Oncology Association). Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J Neurooncol. 104:323–330. 2011. View Article : Google Scholar